White-matter changes associated with a synergetic treatment for myalgic encephalomyelitis/chronic fatigue syndrome

References

• Bjørklund G, Dadar M, Pen JJ, et al. Chronic fatigue syndrome (CFS): suggestions for a nutritional treatment in the therapeutic approach. Biomed Pharmacother. 2019;109:1000–1007. doi:10.1016/j.biopha.2018.10.076
   PubMed Web of Science ®Google Scholar
• Montoya JG, Holmes TH, Anderson JN, et al. Cytokine signature associated with disease severity in chronic fatigue syndrome patients. Proc Natl Acad Sci U S A. 2017;114:E7150–E7158.
   PubMed Web of Science ®Google Scholar
• Fletcher MA, Zeng XR, Barnes Z, et al. Plasma cytokines in women with chronic fatigue syndrome. J Transl Med. 2009;7:96. doi:10.1186/1479-5876-7-96
   PubMed Web of Science ®Google Scholar
• Russell L, Broderick G, Taylor R, et al. Illness progression in chronic fatigue syndrome: a shifting immune baseline. BMC Immunol. 2016;17:1–11. doi:10.1186/s12865-016-0142-3
   PubMed Web of Science ®Google Scholar
• Farkas G, Márton J, Nagy Z, et al. Experimental acute pancreatitis results in increased blood-brain barrier permeability in the rat: a potential role for tumor necrosis factor and interleukin 6. Neurosci Lett. 1998;242:147–150. doi:10.1016/S0304-3940(98)00060-3
   PubMed Web of Science ®Google Scholar
• Soilu-Hänninen M, Erälinna JP, Hukkanen V, et al. Semliki forest virus infects mouse brain endothelial cells and causes blood-brain barrier damage. J Virol. 1994;68:6291–6298. doi:10.1128/jvi.68.10.6291-6298.1994
   PubMed Web of Science ®Google Scholar
• Nakatomi Y, Mizuno K, Ishii A, et al. Neuroinflammation in patients with chronic fatigue syndrome/myalgic encephalomyelitis: An11C-(R)-PK11195 PET study. J Nucl Med. 2014;55:945–950. doi:10.2967/jnumed.113.131045
   PubMed Web of Science ®Google Scholar
• do Campo J, Taylor V. Clinical improvement in patients with ME/CFS with synergistic effect of colchicine and spironolactone targeting inhibition of inflammasome activity. Internal Medicine Journal, Abstracts for the RACP Congress 2022, A Climate for Change, 12–14 May 2022, Melbourne, Victoria, Australia and Online. John Wiley & Sons, Ltd; 2022. p. 13–13.
   Google Scholar
• Mohamed AZ, do Campo J, Del Fante P, et al. Combined oral treatment ameliorates symptoms and white matter microstructural integrity in myalgic encephalomyelitis/chronic fatigue syndrome [Abstract]. Int J Rheum Dis. 2024;27(Suppl. 2):e15172.
   Google Scholar
• Cadegiani FA, Goren A, Wambier CG. Spironolactone may provide protection from SARS-CoV-2: targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS). Med Hypotheses. 2020;143:110112.
   Web of Science ®Google Scholar
• Verma D, Thompson J, Swaminathan S, et al. Spironolactone blocks Epstein-Barr virus production by inhibiting EBV SM protein function. Proc Natl Acad Sci U S A. 2016;113:3609–3614. doi:10.1073/pnas.1523686113
   PubMed Web of Science ®Google Scholar
• Leung YY, Yao Hui LL, Kraus VB. Colchicine – update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015;45(3):341–350. doi:10.1016/j.semarthrit.2015.06.013
   PubMed Web of Science ®Google Scholar
• Polo O, Pesonen P, Tuominen E. Low-dose naltrexone in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Fatigue. 2019;7:207–217.
   Google Scholar
• Kučić N, Rački V, Šverko R, et al. Immunometabolic modulatory role of naltrexone in bv-2 microglia cells. Int J Mol Sci. 2021;22(16):8429. doi:10.3390/ijms22168429
   Web of Science ®Google Scholar
• Agarwal AK, Garg R, Ritch A, et al. Postural orthostatic tachycardia syndrome. Postgrad Med J. 2007;83(981):478–80. doi:10.1136/pgmj.2006.055046
   PubMed Web of Science ®Google Scholar
• Shan ZY, Mohamed AZ, Andersen T, et al. Multimodal MRI of myalgic encephalomyelitis/chronic fatigue syndrome: a cross-sectional neuroimaging study toward its neuropathophysiology and diagnosis. Front Neurol. 2022;13:954142. doi:10.3389/fneur.2022.954142
   PubMed Web of Science ®Google Scholar
• Carruthers BM, Jain AK, De Meirleir KL, et al. Myalgic encephalomyelitis/chronic fatigue syndrome. J Chronic Fatigue Syndr. 2003;11:7–115. doi:10.1300/J092v11n01_02
   Google Scholar
• Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome; Board on the Health of Select Populations; Institute of Medicine. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. Chapter 3: Current Case Definitions and Diagnostic Criteria, Terminology, and Symptom Constructs and Clusters. 2015; Washington (DC): National Academies Press (US); Available from: https://www.ncbi.nlm.nih.gov/books/NBK284898/.
   Google Scholar
• Greenberg S, Aislinn P, Kirsten D. Development and validation of the Fatigue State Questionnaire: preliminary findings. Open Psychol J. 2016;9:50–65. doi:10.2174/1874350101609010050
   Google Scholar
• Mohamed AZ, Lagopoulos J, Nasrallah FA, et al. Self-reported fatigue was associated with increased white-matter alterations in long-term traumatic brain injury and posttraumatic stress disorder patients. Neuroscience. 2023;520:46–57.
   PubMedGoogle Scholar
• Cordero-Grande L, Christiaens D, Hutter J, et al. Complex diffusion-weighted image estimation via matrix recovery under general noise models. Neuroimage. 2019;200:391–404. doi:10.1016/j.neuroimage.2019.06.039
   PubMed Web of Science ®Google Scholar
• Andersson JLR, Skare S, Ashburner J. How to correct susceptibility distortions in spin-echo echo-planar images: application to diffusion tensor imaging. Neuroimage. 2003;20:870–888. doi:10.1016/S1053-8119(03)00336-7
   PubMed Web of Science ®Google Scholar
• Andersson JLR, Sotiropoulos SN. An integrated approach to correction for off-resonance effects and subject movement in diffusion MR imaging. Neuroimage. 2016;125:1063–1078. doi:10.1016/j.neuroimage.2015.10.019
   PubMed Web of Science ®Google Scholar
• Tustison NJ, Avants BB, Cook PA, et al. N4ITK: improved N3 bias correction. IEEE Trans Med Imaging. 2010;29:1310–1320. doi:10.1109/TMI.2010.2046908
   PubMed Web of Science ®Google Scholar
• Smith SM, Jenkinson M, Johansen-Berg H, et al. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage. 2006;31:1487–1505. doi:10.1016/j.neuroimage.2006.02.024
   PubMed Web of Science ®Google Scholar
• Avants BB, Tustison NJ, Song G, et al. A reproducible evaluation of ANTs similarity metric performance in brain image registration. Neuroimage. 2011;54:2033–2044. doi:10.1016/j.neuroimage.2010.09.025
   PubMed Web of Science ®Google Scholar
• Wernze H, Herdegen T. Long-term efficacy of spironolactone on pain, mood, and quality of life in women with fibromyalgia: an observational case series. Scand J Pain. 2014;5:63–71. doi:10.1016/j.sjpain.2013.12.003
   PubMedGoogle Scholar
• Böhm R, Westermann P, Gleim M, et al. High-dose spironolactone lacks effectiveness in treatment of fibromyalgia (RCT). Eur J Pain. 2021;25:1739–1750. doi:10.1002/ejp.1784
   PubMed Web of Science ®Google Scholar
• Wang M, Hammarbäck S, Lindhe B, et al. Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study. Acta Obstet Gynecol Scand. 1995;74:803–808. doi:10.3109/00016349509021201
   PubMed Web of Science ®Google Scholar
• Yuan Y, Heizhati M, Liu Y, et al. Spironolactone is associated with reduced white matter lesion progression in patients with hypertension. Eur J Intern Med. 2023;114:146–149.
   Web of Science ®Google Scholar
• Nakatomi Y, Kuratsune H, Watanabe Y. Neuroinflammation in the brain of patients with myalgic encephalomyelitis/chronic fatigue syndrome. Brain Nerve. 2018;70:19–25.
   PubMedGoogle Scholar
• Wilcox CS, Pitt B. Is spironolactone the preferred renin-angiotensin-aldosterone inhibitor for protection against COVID-19? J Cardiovasc Pharmacol. 2020;77:323–331. doi:10.1097/FJC.0000000000000960
   PubMed Web of Science ®Google Scholar
• Samanani S, Mishra M, Silva C, et al. Screening for inhibitors of microglia to reduce neuroinflammation. CNS Neurol Disord Drug Targets. 2013;12:741–749. doi:10.2174/18715273113126660177
   PubMed Web of Science ®Google Scholar
• Danjuma MI, Sayed R, Aboughalia M, et al. Does colchicine reduce mortality in patients with COVID-19 clinical syndrome? An umbrella review of published meta-analyses. Heliyon. 2023;9(10):e20155. doi:10.1016/j.heliyon.2023.e20155
   PubMed Web of Science ®Google Scholar
• Cabanas H, Muraki K, Eaton-Fitch N, et al. Potential therapeutic benefit of low dose naltrexone in myalgic encephalomyelitis/chronic fatigue syndrome: role of transient receptor potential melastatin 3 ion channels in pathophysiology and treatment. Front Immunol. 2021;12:687806. doi:10.3389/fimmu.2021.687806
   PubMed Web of Science ®Google Scholar
• Ludwig MD, Zagon IS, McLaughlin PJ. Featured article: serum [Met5]-enkephalin levels are reduced in multiple sclerosis and restored by low-dose naltrexone. Exp Biol Med. 2017;242(15):1524–1533. doi:10.1177/1535370217724791
   Web of Science ®Google Scholar
• Bruun KD, Amris K, Vaegter HB, et al. Low-dose naltrexone for the treatment of fibromyalgia: protocol for a double-blind, randomized, placebo-controlled trial. Trials. 2021;22:804.
   PubMedGoogle Scholar